Почетна › Прекумерна телесна тежина › Северна Каролина
Клинички испитувања за Прекумерна телесна тежина во Северна Каролина
40 студии за Прекумерна телесна тежина бараат учесници на локации во Северна Каролина.
Градови во Северна Каролина
- Havelock17 студии
- Charlotte15 студии
- Greensboro12 студии
- Wilmington11 студии
- Durham7 студии
- Winston-Salem6 студии
- Statesville5 студии
- Raleigh5 студии
- Cary4 студии
- Fayetteville4 студии
- New Bern4 студии
- Greenville3 студии
Официјален текст на студијата (англиски)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Medication Management /ID# 281965, Greensboro
- Monroe Biomedical Research /ID# 282009, Monroe
- Centricity Research - Morehead city /ID# 283264, Morehead City
- и уште 2
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT07752979FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
- University of North Carolina at Chapel Hill, Chapel Hill
Се регрутира
Возраст од 18 до 75 · Сите полови · Ажурирано 29.9.2026 · NCT06724406Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- TMA Headlands, Wilmington
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 28.9.2026 · NCT07837973AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Medication Mgmnt, LLC_Grnsboro, Greensboro
- Accellacare of Raleigh, Raleigh
- Accellacare-Salisbury PMG Res, Salisbury
- и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07720271A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- PharmQuest Life Sciences LLC, Greensboro
- Piedmont Healthcare/Research, Statesville
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07668414A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Medication Management, Greensboro
- Monroe Biomedical Research, Monroe
- West Clinical Research, Morehead City
- и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07794579A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Medication Management, LLC, Greensboro
- Accellacare - Wilmington, Wilmington
- Jeffrey Coleman, OD, Wilmington
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07595549A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Statesville
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07776509Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Coastal Research Institute - Fayetteville, Fayetteville
Се регрутираФаза 3
Возраст од 18 до 70 · Сите полови · Ажурирано 24.9.2026 · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- UNC Children's Hospital, Chapel Hill
- Duke Children's Primary Care, Durham
- Lucas Research, Inc, Morehead City
Се регрутираФаза 3
Возраст од 6 до 17 · Сите полови · Ажурирано 24.9.2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Coastal Research Institute - Fayetteville, Fayetteville
Се регрутираФаза 3
Возраст од 18 до 70 · Сите полови · Ажурирано 24.9.2026 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- PharmQuest Life Sciences, LLC, Greensboro
- West Clinical Research, Morehead City
- Trial Management Associates - Wilmington - Floral Parkway, Wilmington
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07282600A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- University of North Carolina Medical Center, Chapel Hill
- Medication Management, Greensboro
- Carteret Medical Group, Morehead City
- и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07392190A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Monroe
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Novant Health Heart and Vascular Institute, Charlotte
- Velocity Clinical Research - Durham, Durham
- Moses H Cone Memorial Hospital, Greensboro
- и уште 7
Се регрутираФаза 3
Возраст од 45 до 99 · Сите полови · Ажурирано 22.9.2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Monroe Biomedical Research, Monroe
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Medication Management, Greensboro
- Monroe Biomedical Research, Monroe
- Lucas Research, Inc, Morehead City
- и уште 1
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 22.9.2026 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Charlotte
- AURORA-1 Clinical Site, Greenville
- AURORA-1 Clinical Site, Morehead City
- и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Charlotte
- AURORA-2 Clinical Site, Durham
- AURORA-2 Clinical Site, Greenville
- и уште 2
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Centricity Research Morehead City Multispeciality, Morehead City
- Wake Forest University Health Sciences, Winston-Salem
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Lucas Research, Inc., Morehead City
- Shelby Clinical Research, Shelby
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 14.9.2026 · NCT06897475A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Charlotte
- ACCOMPLISH-2 Research Site, Durham
- ACCOMPLISH-2 Research Site, Fayetteville
- и уште 2
Се регрутираФаза 3Добредојдени се здрави волонтери
Возраст од 18 до 79 · Сите полови · Ажурирано 11.9.2026 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Medication Management, Greensboro
- Monroe Biomedical Research, Monroe
- Lucas Research, Inc, Morehead City
- и уште 1
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 8.9.2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Revival Research Institute, LLC, Cary
- Onsite Clinical Solutions - Huntersville, Huntersville
Се регрутираФаза 4
Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT06857942A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- PharmQuest, Greensboro
- KDCILM, LLC & Accellacare US, Inc., Wilmington
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT07745504Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Greensboro
- Kailera Clinical Site, Monroe
- Kailera Clinical Site, Morehead City
- и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Accellacare of Hickory, Hickory
- Carolina Research Center Inc, Shelby
Се регрутираФаза 3
Возраст од 18 до 99 · Сите полови · Ажурирано 3.9.2026 · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Morehead City
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- West Clinical Research, Morehead City
Се регрутираФаза 3
Возраст од 18 до 99 · Сите полови · Ажурирано 3.9.2026 · NCT07684144Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Centricity Research Morehead City Specialty, Morehead City
- Accellacare of Raleigh, Raleigh
- Accellacare Research of Wilmington, Wilmington
Се регрутираФаза 3
Возраст од 18 до 99 · Сите полови · Ажурирано 27.8.2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Statesville
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.8.2026 · NCT07784725AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Piedmont Healthcare/Research, Statesville
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT07509307Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Charlotte
- ACCOMPLISH-1 Research Site, Durham
- ACCOMPLISH-1 Research Site, Fayetteville
- и уште 3
Се регрутираФаза 3
Возраст од 18 до 79 · Сите полови · Ажурирано 10.8.2026 · NCT07654361Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
- Monroe Biomedical Research, LLC, Monroe
- Accellacare, Wilmington
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 25.6.2026 · NCT07607587A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.
- Monroe Biomedical Research, Monroe
Се регрутираФаза 2
Возраст од 18 до 60 · Сите полови · Ажурирано 22.6.2026 · NCT07570758Pregnancy Exercise Mode Effect on Childhood Obesity
- East Carolina University, Greenville
Се регрутираДобредојдени се здрави волонтери
Возраст од 18 до 45 · Жени · Ажурирано 4.6.2026 · NCT04805502NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
- Wake Forest University Health Sciences, Winston-Salem
Се регрутираДобредојдени се здрави волонтери
Возраст од 18 до 39 · Жени · Ажурирано 27.2.2026 · NCT05674799A Mobile Intervention to Reduce Pain and Improve Health-III
- Wake Forest University, Winston-Salem
Се регрутираФаза 2
Возраст 65 и постари · Сите полови · Ажурирано 20.2.2026 · NCT06623669MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
- True You Weight Loss, Cary
- True You Weight Loss, Cary
Се регрутира
Возраст од 21 до 65 · Сите полови · Ажурирано 21.3.2025 · NCT06734312REvision of VSG with Ablation of the Mucosa Procedure
- True You Weight Loss, Cary
Се регрутира
Возраст од 22 до 60 · Сите полови · Ажурирано 5.11.2024 · NCT06671119Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.